| Next 10 |
Ad
TIL News and Press Instil Bio Inc.
News | Instil Bio Inc. (NASDAQ:TIL)
-
2023-08-14 09:53:11 ET Instil Bio press release ( NASDAQ: TIL ): Q2 GAAP EPS of -$0.14. As of June 30, 2023, Instil had cash, cash equivalents, restricted cash and marketable securities of $202.9 million, which consists of $21.8 million in cash and cash equi...
-
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facility with additional process improvements ...
-
Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023 Initial clinical data from ITI...
-
2023-05-11 09:51:16 ET Instil Bio press release ( NASDAQ: TIL ): Q1 GAAP EPS of -$0.44. As of March 31, 2023, Instil had cash, cash equivalents, restricted cash and marketable securities of $223.9 million, which consists of $27.4 million in cash and cash e...
-
ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H ’ 2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”...
-
2023-03-31 09:19:44 ET Instil Bio press release ( NASDAQ: TIL ): Q4 GAAP EPS of -$0.41 in-line. As of December 31, 2022, Instil had $260.9 million in total cash and cash equivalents and marketable securities, comprised of $43.7 million in cash and cash equiv...
-
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 DALLAS, March 31, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil&#x...
-
Instil Bio ( NASDAQ: TIL ) said it would extend reduction-in-force to a team of about 15 employees in the U.S. to lead global business operations, including the consolidation of clinical manufacturing and trial operations of its CoStAR-TIL to its active Manchester, U.K. operations. ...
-
Company anticipates cash resources to provide runway beyond 2026 Initial clinical data from the ITIL-306 program expected in 2023 Instil is consolidating manufacturing and Phase 1 clinical trial of CoStAR-TIL™ to its operations in Manchester, U.K. Instil to extend...
-
Penny Stocks, News, & Market Momentum This Week This is the first full week of the New Year and one that many investors will be focused on. Not only will we see Federal Reserve Chair Jerome Powell’s first major speech of the year, but there’s also no time wasted for the firs...
Stock Information
Instil Bio Inc. Company Name:
TIL Stock Symbol:
NASDAQ Market:
Ad
-
Better For You Wellness, Inc. (OTCQB: BFYW), an Ohio-based wellness company at the forefront of plant-based and scien...
-
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facility with additional process improvements ...
-
Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023 Initial clinical data from ITI...